CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2018 Genitourinary Cancers Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Slovin Discusses a Study Comparing Cardiovascular Events With Degarelix, Leuprolide in Prostate Cancer
Dr. Gulley Discusses a Phase II Study of Olaparib and Durvalumab in mCRPC
Dr. Bellmunt Discusses Follow-Up Data for Pembrolizumab vs Chemotherapy in Bladder Cancer
Oncology Conference Articles
Pembrolizumab Plus Axitinib Active in Frontline RCC
Antitumor activity of the combination of axitinib (Inlyta) and pembrolizumab (Keytruda) is superior to that expected from axitinib or PD-1/PD-L1 pathway inhibitor monotherapy in treatment-naïve patients with advanced renal cell carcinoma.
Cabozantinib Proves Superior to Sunitinib in All Subgroups Examined in CABOSUN
Cabozantinib (Cabometyx) improved progression-free survival as initial systemic therapy across subgroups of patients with intermediate- and poor-risk advanced RCC enrolled in the randomized phase II CABOSUN trial.
Erdafitinib Elicits High Response Rates in FGFR-Positive Urothelial Cancer
Erdafitinib showed responses in more than one-third of patients with pretreated metastatic or unresectable FGFR alteration-positive urothelial carcinoma.
Pembrolizumab Survival Benefit Sustained in 2-Year Urothelial Cancer Data
Two-year follow-up data showed sustained improvements in overall survival with pembrolizumab over chemotherapy in pretreated patients with locally advanced or recurrent urothelial cancer.
SM-88 Delays Recurrence for Nonmetastatic Prostate Cancer
Data from the first 13 evaluable patients enrolled in a phase II study of SM-88 showed a reduction in circulating tumor cells, a slowing of prostate-specific antigen increase, and delayed radiographic progression of disease in nonmetastatic prostate cancer.
Olaparib/Durvalumab Combo Shows Promise in mCRPC
The PARP inhibitor olaparib appeared to complement the antitumor activity of the PD-L1 inhibitor durvalumab in unselected men with metastatic castrate-resistant prostate cancer, according to findings from a phase II study presented at the 2018 Genitourinary Cancers Symposium.
New Model Predicts Survival Following Treatment With Atezolizumab for Bladder Cancer
A new model based on 6 clinical factors may be able to predict overall survival for patients with advanced urothelial cancers being treated with the PD-L1 inhibitor atezolizumab.
Docetaxel Adds to QALY in Advanced Prostate Disease
The addition of docetaxel (Taxotere) to frontline long-term hormone therapy for advanced prostate cancer improved quality of life and reduced the need for subsequent therapy, contributing to lower overall costs in the nonmetastatic setting.
Apalutamide Delays Metastasis by Over 2 Years in Prostate Cancer
Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer, according to findings from the phase III SPARTAN trial.
Atezolizumab Combo Improves PFS by 3.5 Months in mRCC
The combination of atezolizumab and bevacizumab reduced the risk of progression or death by 26% compared with sunitinib for patients with untreated PD-L1–positive metastatic renal cell carcinoma.
Enzalutamide More Than Doubles MFS for Nonmetastatic CRPC
Treatment with the combination of enzalutamide and androgen deprivation therapy reduced the risk of metastases or death by 71% compared with ADT alone in patients with nonmetastatic castration-resistant prostate cancer.
FDA Approvals in Myeloma and aTTP, Priority Review Designations in RCC and HNSCC, and More
Novel Agents Spark New Approaches for Triple-Negative Breast Cancer
Hereditary Prostate Cancer—What Urologists Should Know
FDA Grants Pembrolizumab/Axitinib Combo Priority Review for Frontline RCC
Targeting BCL-2 in Hematologic Malignancies
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.